<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02858037</url>
  </required_header>
  <id_info>
    <org_study_id>MTN-025</org_study_id>
    <nct_id>NCT02858037</nct_id>
  </id_info>
  <brief_title>Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women</brief_title>
  <official_title>A Phase 3B Open-Label Follow-on Trial to Assess the Continued Safety of and Adherence to a Vaginal Ring Containing Dapivirine in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>International Partnership for Microbicides, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>International Partnership for Microbicides, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV Open-label Prevention Extension (HOPE).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase 3B Open-Label Follow-on Trial to Assess the Continues Safety of and Adherence to a&#xD;
      Vaginal ring Containing Dapivirine in Women&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Actual">October 10, 2018</completion_date>
  <primary_completion_date type="Actual">October 10, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to be replaced each month for a total period of 12 months of use.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessing the Dapivirine Ring open label use Safety Profile by Grade 2, Grade 3 and all serious AEs</measure>
    <time_frame>13 months</time_frame>
    <description>To characterize the safety profile associated with the open label use of the dapivirine vaginal matrix ring (25 mg) in women</description>
  </primary_outcome>
  <primary_outcome>
    <measure>By measuring the residual levels of dapivirine in returned vaginal rings and Blood dapivirine levels</measure>
    <time_frame>13 months</time_frame>
    <description>To characterize adherence to the open label use of the dapivirine vaginal matrix ring (25 mg) in women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-1 infection as measured by the protocol algorithm</measure>
    <time_frame>13 months</time_frame>
    <description>To assess incidence of HIV-1 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-1 drug resistance mutations among participants who acquire HIV-1, as measured by standard genotype analysis and more sensitive methods to detect low frequency drug-resistant variants</measure>
    <time_frame>13 months</time_frame>
    <description>To assess the frequency of HIV-1 drug resistance in women who acquire HIV-&#xD;
1 infection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1576</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>HIV Open-label Prevention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following demonstration of safety and efficacy of the dapivirine vaginal ring in MTN-020, eligible MTN-020 participants will be offered enrollment into MTN-025, a trial designed to obtain additional safety and adherence data in women&#xD;
MTN-020:NCT01617096 MTN-025: NCT02858037</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Dapivirine Vaginal Ring</intervention_name>
    <description>Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.</description>
    <arm_group_label>HIV Open-label Prevention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Women must meet all of the following criteria to be eligible for inclusion in the study&#xD;
&#xD;
          1. Previously enrolled in MTN-020 (ASPIRE)&#xD;
&#xD;
          2. Able and willing to provide written informed consent to be screened for and to take&#xD;
             part in the study&#xD;
&#xD;
          3. Able and willing to provide adequate locator information, as defined in site SOPs&#xD;
&#xD;
          4. HIV-uninfected based on testing performed by study staff at Screening and Enrollment&#xD;
&#xD;
          5. Using an effective method of contraception at Enrollment, and intending to use an&#xD;
             effective method for the duration of study participation; effective methods include&#xD;
             hormonal methods (except contraceptive ring); intrauterine contraceptive device&#xD;
             (IUCD); and sterilization (of participant, as defined in site SOPs)&#xD;
&#xD;
          6. At Screening and Enrollment, agrees not to participate in other research studies&#xD;
             involving drugs, medical devices, vaginal products, or vaccines for the duration of&#xD;
             study participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Women who meet any of the following criteria will be excluded from the study&#xD;
&#xD;
          1. Study product use permanently discontinued in response to an AE or safety related&#xD;
             concern while taking part in the MTN-020 (ASPIRE) trial&#xD;
&#xD;
          2. Per participant report at Screening:&#xD;
&#xD;
               1. Plans to relocate away from the study site during study participation&#xD;
&#xD;
               2. Plans to travel away from the study site for more than three consecutive months&#xD;
                  during study participation&#xD;
&#xD;
          3. Per participant report at Enrollment, currently taking Post-Exposure Prophylaxis (PEP)&#xD;
&#xD;
          4. With the exception of MTN-020 (ASPIRE), participation in any other research study&#xD;
             involving drugs, medical devices, vaginal products, or vaccines, within 60 days of&#xD;
             enrollment&#xD;
&#xD;
          5. Is pregnant at Screening/Enrollment or planning to become pregnant in the&#xD;
             participant's anticipated study participation period&#xD;
&#xD;
          6. Currently breastfeeding&#xD;
&#xD;
          7. Diagnosed with urinary tract infection (UTI), pelvic inflammatory disease (PID), STI&#xD;
             or reproductive tract infection (RTI) requiring treatment per WHO guidelines&#xD;
&#xD;
          8. At Screening, has a clinically apparent Grade 3 pelvic exam finding (observed by study&#xD;
             staff) as per the Division of AIDS Table for Grading the Severity of Adult and&#xD;
             Pediatric Adverse Events Version 1.0, December, 2004 (Clarification dated August&#xD;
             2009), Addendum 1-Female Genital Grading Table for Use in Microbicide Studies&#xD;
&#xD;
          9. Has any of the following laboratory abnormalities at Screening Visit:&#xD;
&#xD;
               1. Aspartate aminotransferase (AST) or alanine transaminase (ALT) &gt; Grade 3*&#xD;
&#xD;
               2. Creatinine &gt; Grade 3*&#xD;
&#xD;
               3. Hemoglobin &gt; Grade 3*&#xD;
&#xD;
               4. Platelet count &gt; Grade 3*&#xD;
&#xD;
               5. Pap result â‰¥ Grade 3 according to the Female Genital Grading Table for Use in&#xD;
                  Microbicide Studies Addendum 1 to the DAIDS Table for Grading Adult and Pediatric&#xD;
                  Adverse Events, Version 1.0, December 2004 (Clarification dated August 2009)&#xD;
&#xD;
         10. Has any significant medical condition or other condition that, in the opinion of the&#xD;
             IoR/designee, would preclude informed consent, make study participation unsafe,&#xD;
             complicate interpretation of study outcome data, or otherwise interfere with achieving&#xD;
             the study objectives&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Prevention for HIV and AIDS Project</name>
      <address>
        <city>Pinetown</city>
        <state>KwaZulu Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>August 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2016</study_first_posted>
  <disposition_first_submitted>February 18, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>February 18, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 25, 2020</disposition_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapivirine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

